Pre-transplantation plasma vitamin D levels and acute graft-versus-host disease after myeloablative hematopoietic cell transplantation in adults

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Pre-transplantation plasma vitamin D levels and acute graft-versus-host disease after myeloablative hematopoietic cell transplantation in adults. / Gjærde, Lars Klingen; Ostrowski, Sisse Rye; Andersen, Niels Smedegaard; Friis, Lone Smidstrup; Kornblit, Brian; Petersen, Søren Lykke; Schjødt, Ida; Sengeløv, Henrik.

I: Transplant Immunology, Bind 68, 101437, 10.2021.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Gjærde, LK, Ostrowski, SR, Andersen, NS, Friis, LS, Kornblit, B, Petersen, SL, Schjødt, I & Sengeløv, H 2021, 'Pre-transplantation plasma vitamin D levels and acute graft-versus-host disease after myeloablative hematopoietic cell transplantation in adults', Transplant Immunology, bind 68, 101437. https://doi.org/10.1016/j.trim.2021.101437

APA

Gjærde, L. K., Ostrowski, S. R., Andersen, N. S., Friis, L. S., Kornblit, B., Petersen, S. L., Schjødt, I., & Sengeløv, H. (2021). Pre-transplantation plasma vitamin D levels and acute graft-versus-host disease after myeloablative hematopoietic cell transplantation in adults. Transplant Immunology, 68, [101437]. https://doi.org/10.1016/j.trim.2021.101437

Vancouver

Gjærde LK, Ostrowski SR, Andersen NS, Friis LS, Kornblit B, Petersen SL o.a. Pre-transplantation plasma vitamin D levels and acute graft-versus-host disease after myeloablative hematopoietic cell transplantation in adults. Transplant Immunology. 2021 okt.;68. 101437. https://doi.org/10.1016/j.trim.2021.101437

Author

Gjærde, Lars Klingen ; Ostrowski, Sisse Rye ; Andersen, Niels Smedegaard ; Friis, Lone Smidstrup ; Kornblit, Brian ; Petersen, Søren Lykke ; Schjødt, Ida ; Sengeløv, Henrik. / Pre-transplantation plasma vitamin D levels and acute graft-versus-host disease after myeloablative hematopoietic cell transplantation in adults. I: Transplant Immunology. 2021 ; Bind 68.

Bibtex

@article{70a2dd420ecb4ec982861a3005238a34,

title = "Pre-transplantation plasma vitamin D levels and acute graft-versus-host disease after myeloablative hematopoietic cell transplantation in adults",

abstract = "Background: The association between vitamin D and acute graft-versus-host disease (GvHD) remains controversial, especially for patients receiving myeloablative conditioning. Methods: We measured pre-transplantation plasma vitamin D (25-hydroxyvitamin D3 + D2) levels by competitive electrochemiluminescence in plasma samples from 116 adult patients who underwent a myeloablative allogeneic transplantation at Rigshospitalet, Copenhagen between July 2015 and August 2018. Results: The median (Q1, Q3) pre-transplantation plasma vitamin D level was 64 (47, 85) nmol/L (normal range: 50–160 nmol/L). Vitamin D insufficiency (<50 nmol/L) and moderate deficiency (<25 nmol/L) were observed in 29% and 8% of patients, respectively. No patients had a severe deficiency (<12 nmol/L). Pre-transplantation vitamin D levels were slightly higher in patients who later developed grade II–IV acute GvHD (mean difference: 8.1 nmol/L), but the 95% confidence interval [CI] encompassed clinically insignificant differences (CI: −2.2, 19.2 nmol/L). From multivariable logistic regression, we found that a patient with a pre-transplantation vitamin D level of 85 nmol/L (Q3) had 1.5 times higher odds of grade II–IV acute GvHD than a patient with a level of 47 nmol/L (Q1; CI of odds ratio: 0.84, 2.7; adjusted for patient age, donor type, use of anti-thymocyte globulin, and use of 12 Gy total-body irradiation). Patients with pre-transplantation vitamin D insufficiency (N = 34) had a cumulative incidence of grade II–IV acute GvHD similar to that of patients with vitamin D sufficiency (26% [CI: 11%, 42%] versus 35% [CI: 25%, 46%], respectively). Conclusions: Our data did not support an association between pre-transplantation vitamin D levels or vitamin D insufficiency and acute GvHD in adult patients receiving myeloablative conditioning.",

keywords = "Acute graft-versus-host disease, Allogeneic hematopoietic cell transplantation, Myeloablative conditioning, Vitamin D",

author = "Gj{\ae}rde, {Lars Klingen} and Ostrowski, {Sisse Rye} and Andersen, {Niels Smedegaard} and Friis, {Lone Smidstrup} and Brian Kornblit and Petersen, {S{\o}ren Lykke} and Ida Schj{\o}dt and Henrik Sengel{\o}v",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2021",

month = oct,

doi = "10.1016/j.trim.2021.101437",

language = "English",

volume = "68",

journal = "Transplant Immunology",

issn = "0966-3274",

publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Pre-transplantation plasma vitamin D levels and acute graft-versus-host disease after myeloablative hematopoietic cell transplantation in adults

AU - Gjærde, Lars Klingen

AU - Ostrowski, Sisse Rye

AU - Andersen, Niels Smedegaard

AU - Friis, Lone Smidstrup

AU - Kornblit, Brian

AU - Petersen, Søren Lykke

AU - Schjødt, Ida

AU - Sengeløv, Henrik

PY - 2021/10

Y1 - 2021/10

N2 - Background: The association between vitamin D and acute graft-versus-host disease (GvHD) remains controversial, especially for patients receiving myeloablative conditioning. Methods: We measured pre-transplantation plasma vitamin D (25-hydroxyvitamin D3 + D2) levels by competitive electrochemiluminescence in plasma samples from 116 adult patients who underwent a myeloablative allogeneic transplantation at Rigshospitalet, Copenhagen between July 2015 and August 2018. Results: The median (Q1, Q3) pre-transplantation plasma vitamin D level was 64 (47, 85) nmol/L (normal range: 50–160 nmol/L). Vitamin D insufficiency (<50 nmol/L) and moderate deficiency (<25 nmol/L) were observed in 29% and 8% of patients, respectively. No patients had a severe deficiency (<12 nmol/L). Pre-transplantation vitamin D levels were slightly higher in patients who later developed grade II–IV acute GvHD (mean difference: 8.1 nmol/L), but the 95% confidence interval [CI] encompassed clinically insignificant differences (CI: −2.2, 19.2 nmol/L). From multivariable logistic regression, we found that a patient with a pre-transplantation vitamin D level of 85 nmol/L (Q3) had 1.5 times higher odds of grade II–IV acute GvHD than a patient with a level of 47 nmol/L (Q1; CI of odds ratio: 0.84, 2.7; adjusted for patient age, donor type, use of anti-thymocyte globulin, and use of 12 Gy total-body irradiation). Patients with pre-transplantation vitamin D insufficiency (N = 34) had a cumulative incidence of grade II–IV acute GvHD similar to that of patients with vitamin D sufficiency (26% [CI: 11%, 42%] versus 35% [CI: 25%, 46%], respectively). Conclusions: Our data did not support an association between pre-transplantation vitamin D levels or vitamin D insufficiency and acute GvHD in adult patients receiving myeloablative conditioning.

AB - Background: The association between vitamin D and acute graft-versus-host disease (GvHD) remains controversial, especially for patients receiving myeloablative conditioning. Methods: We measured pre-transplantation plasma vitamin D (25-hydroxyvitamin D3 + D2) levels by competitive electrochemiluminescence in plasma samples from 116 adult patients who underwent a myeloablative allogeneic transplantation at Rigshospitalet, Copenhagen between July 2015 and August 2018. Results: The median (Q1, Q3) pre-transplantation plasma vitamin D level was 64 (47, 85) nmol/L (normal range: 50–160 nmol/L). Vitamin D insufficiency (<50 nmol/L) and moderate deficiency (<25 nmol/L) were observed in 29% and 8% of patients, respectively. No patients had a severe deficiency (<12 nmol/L). Pre-transplantation vitamin D levels were slightly higher in patients who later developed grade II–IV acute GvHD (mean difference: 8.1 nmol/L), but the 95% confidence interval [CI] encompassed clinically insignificant differences (CI: −2.2, 19.2 nmol/L). From multivariable logistic regression, we found that a patient with a pre-transplantation vitamin D level of 85 nmol/L (Q3) had 1.5 times higher odds of grade II–IV acute GvHD than a patient with a level of 47 nmol/L (Q1; CI of odds ratio: 0.84, 2.7; adjusted for patient age, donor type, use of anti-thymocyte globulin, and use of 12 Gy total-body irradiation). Patients with pre-transplantation vitamin D insufficiency (N = 34) had a cumulative incidence of grade II–IV acute GvHD similar to that of patients with vitamin D sufficiency (26% [CI: 11%, 42%] versus 35% [CI: 25%, 46%], respectively). Conclusions: Our data did not support an association between pre-transplantation vitamin D levels or vitamin D insufficiency and acute GvHD in adult patients receiving myeloablative conditioning.

KW - Acute graft-versus-host disease

KW - Allogeneic hematopoietic cell transplantation

KW - Myeloablative conditioning

KW - Vitamin D

U2 - 10.1016/j.trim.2021.101437

DO - 10.1016/j.trim.2021.101437

M3 - Journal article

C2 - 34273495

AN - SCOPUS:85110308387

VL - 68

JO - Transplant Immunology

JF - Transplant Immunology

SN - 0966-3274

M1 - 101437

ER -

ID: 275771906